THE EFFICIENCY AND TOLERABILITY OF SINGLE-DOSE THERAPY FOR BACTERIAL VAGINOSIS ASSOCIATED WITH MYCOPLASMA INFECTION

Objective. To analyze the efficiency and acceptability of single-dose therapy (fluconazole, azithromycin, secnidazole) for bacterial vaginosis associated with Mycoplasma infection. Subjects and methods. An open-labeled randomized clinical trial was conducted. The trial enrolled 80 patients aged 18 to 40 years (mean age 28.9±5.5 years) divided into two groups. Thirty married couples (60 patients) in which both the men and women were treated with a single safocid dose were included into Group 1. Group 2 comprised 20 married couples in which only the women used safocid once and their sexual partner did not. All the patients underwent examination of the external genitalia, speculum examination of the vagina and cervix uteri, and bimanual study. Laboratory studies encompassed clinical blood and urine analyses, tests for syphilis, HIV, Chlamydia, Mycoplasma, and Ureaplasma, microscopy of Gram-stained smears and discharges from the cervical canal, urethra, and rectum for the women and microscopy of Gram-stained smears and discharges from the urethra and rectum for the men. Results. The treatment of women infected with Gardnerella vaginalis, Ureaplasma urealyticum, and Mycoplasma hominis showed a significant reduction (p < 0.001). Pronounced clinical and laboratory effects were noted in 87 and 84.8% of the female patients, respectively. A marked clinical effect was seen in all their male partners included into the study. The assessment of therapeutic convenience showed that all the men and 93% of their sexual partners were satisfied with the performed therapy and considered it convenient. Conclusion. Single-dose combination therapy is effective and well tolerated.

single-dose therapy, bacterial vaginosis, partner treatment, sexually transmitted infections